Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Alternatively, they may inject the full recommended dose but do so less often than once per week
Patent expiry is a natural part of the pharmaceutical product lifecycle, and we are well-positioned to navigate this evolving landscape, said Vikrant Shrotriya, Managing Director, Novo Nordisk India
The SUSTAIN 10 trial demonstrated a 1.7% reduction at week 30
It is suitable for individuals who have already achieved desired weight loss, have healthy lifestyle habits, low baseline hunger, and consistent metabolic markers
As one of only three glucagon-like peptide 1 (GLP-1) receptor agonists approved for weight loss in people with obesity or who are overweight, Wegovy (semaglutide) is on its way to becoming as popular as its Type 2 diabetes-approved counterpart, Ozempic
Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group
US$ 23.17
US$ 28.35
US$ 22.14
US$ 27.34
